Ata-Ali F, Ata-Ali J, Flichy-Fernández AJ, Bagán JV. Osteonecrosis of
the jaws in patients treated with bisphosphonates. J Clin Exp Dent.
2012;4(1):e60-5.
doi:10.4317/jced.4.50649
http://dx.doi.org/doi:10.4317/jced.4.50649
References
1. Marx RE. Pamidronate (Aredia) and
zoledronate (Zometa) induced avascular necrosis of the jaws: a growing
epidemic. J Oral Maxillofac Surg. 2003;61:1115-7.
http://dx.doi.org/10.1016/S0278-2391(03)00720-1
2. Ruggiero SL, Dodson TB, Assael LA,
Landesberg R, Marx RE, Mehrotra B; American Association of Oral and
Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons
position paper on bisphosphonate-related osteonecrosis of the jaws--2009
update. J Oral Maxillofac Surg. 2009;67:2-12.
http://dx.doi.org/10.1016/j.joms.2009.01.009
PMid:19371809
3. Bittner T, Lorbeer N, Reuther T,
Böhm H, Kübler AC, Müller-Richter UD. Hemimandibulectomy after bisphosphonate
treatment for complex regional pain syndrome: A case report and review on the
prevention and treatment of bisphosphonate-related osteonecrosis of the jaw.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Mar 30. [Epub ahead of
print].
4. Borromeo GL, Tsao CE, Darby IB,
Ebeling PR. A review of the clinical implications of bisphosphonates in
dentistry. Aust Dent J. 2011;56:2-9.
http://dx.doi.org/10.1111/j.1834-7819.2010.01283.x
PMid:21332734
5. Gupta S, Jain P, Kumar P, Parikh
PM. Zoledronic acid induced osteonecrosis of tibia and femur. Indian J Cancer.
2009;46:249–250.
http://dx.doi.org/10.4103/0019-509X.52967
PMid:19574685
6. Landesberg R, Woo V, Cremers S,
Cozin M, Marolt D, Vunjak-Novakovic G, et al. Potential pathophysiological
mechanisms in osteonecrosis of the jaw. Ann N Y Acad Sci. 2011;1218:62-79.
http://dx.doi.org/10.1111/j.1749-6632.2010.05835.x
PMid:21291478
7. Hoefert S, Eufinger H. Relevance of
a prolonged preoperative antibiotic regime in the treatment of
bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg.
2011;69:362-80.
http://dx.doi.org/10.1016/j.joms.2010.06.200
PMid:21122968
8. Bagán JV, Diz-Dios P, Gallego L,
Infante-Cossío P, Jiménez Y, Junquera LM, et al. Recomendaciones para la
prevención de la osteonecrosis de los maxilares (ONM) en pacientes con cáncer
tratados con bisfosfonatos intravenosos. Med Oral Patol Oral Cir Bucal.
2008;13:161-7.
9. Manfredi M, Merigo E, Guidotti R,
Meleti M, Vescovi P. Bisphosphonate-related osteonecrosis of the jaws: a case
series of 25 patients affected by osteoporosis. Int J Oral Maxillofac Surg.
2011;40:277-84.
http://dx.doi.org/10.1016/j.ijom.2010.11.002
PMid:21163625
10. Yoneda T, Hagino H, Sugimoto T,
Ohta H, Takahashi S, Soen S, et al. Bisphosphonate-related osteonecrosis of the
jaw: position paper from the Allied Task Force Committee of Japanese Society
for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of
Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and
Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab.
2010;28:365-83.
http://dx.doi.org/10.1007/s00774-010-0162-7
PMid:20333419
11. Narongroeknawin P, Danila MI,
Humphreys LG Jr, Barasch A, Curtis JR. Bisphosphonate-associated osteonecrosis
of the jaw, with healing after teriparatide: a review of the literature and a
case report. Spec Care Dentist. 2010;30:77-82.
http://dx.doi.org/10.1111/j.1754-4505.2009.00128.x
PMid:20415805
12. Pautke C, Bauer F, Otto S,
Tischer T, Steiner T, Weitz J, et al. Fluorescence-guided bone resection in
bisphosphonate-related osteonecrosis of the jaws: first clinical results of a
prospective pilot study. J Oral Maxillofac Surg. 2011;69:84-91.
http://dx.doi.org/10.1016/j.joms.2010.07.014
PMid:20971542
13. Ferlito S, Puzzo S, Liardo C.
Preventive protocol for tooth extractions in patients treated with zoledronate:
a case series. J Oral Maxillofac Surg. 2011;69:e1-4.
http://dx.doi.org/10.1016/j.joms.2010.10.055
PMid:21316136
14. Wutzl A, Pohl S, Sulzbacher I,
Seemann R, Lauer G, Ewers R, et al. Factors influencing surgical treatment of
bisphosphonaterelated osteonecrosis of the jaws. Head Neck. 2011 Mar 11. [Epub
ahead of print]
15. Maurer P, Sandulescu T, Kriwalsky
MS, Rashad A, Hollstein S, Stricker I, et al. Bisphosphonate-related osteonecrosis
of the maxilla and sinusitis maxillaris. Int J Oral Maxillofac Surg.
2011;40:285-91.
http://dx.doi.org/10.1016/j.ijom.2010.11.006
PMid:21163624
16. Scoletta M, Arduino PG, Pol R, Arata
V, Silvestri S, Chiecchio A, et al. Initial experience on the outcome of teeth
extractions in intravenous bisphosphonate-treated patients: a cautionary
report. J Oral Maxillofac Surg. 2011;69:456-62.
http://dx.doi.org/10.1016/j.joms.2010.07.026
PMid:21129835
17. Bagan J, Scully C, Sabater V,
Jimenez Y. Osteonecrosis of the jaws in patients treated with intravenous
bisphosphonates (BRONJ): A concise update. Oral Oncol. 2009;45:551-4.
http://dx.doi.org/10.1016/j.oraloncology.2009.01.002
PMid:19251474
18. Reid IR, Cundy T. Osteonecrosis
of the jaw. Skeletal Radiol. 2009;38:5-9.
http://dx.doi.org/10.1007/s00256-008-0549-x
PMid:18649076
http://dx.doi.org/10.1007/s00256-008-0596-3
19. Kim RH, Lee RS, Williams D, Bae
S, Woo J, Lieberman M, et al. Bisphosphonates Induce Senescence in Normal Human
Oral Keratinocytes. J Dent Res. 2011 Mar 22. [Epub ahead of print].
20. Aghaloo TL, Felsenfeld AL,
Tetradis S. Osteonecrosis of the jaw in a patient on denosumab. J Oral
Maxillofac Surg 2010;68:959–63.
http://dx.doi.org/10.1016/j.joms.2009.10.010
PMid:20149510
PMCid:2880179
21. Feller L, Wood NH, Raubenheimer
EJ, Meyerov R, Lemmer J. Alveolar bone necrosis and spontaneous tooth exfoliation
in an HIVseropositive subject with herpes zoster. SADJ 2008;63:106 –10.
PMid:18561810
22. Marx RE, Cillo JE Jr, Ulloa JJ.
Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk
using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg.
2007;65:2397-410.
http://dx.doi.org/10.1016/j.joms.2007.08.003
PMid:18022461
23. Grant BT, Amenedo C, Freeman K, Kraut
RA. Outcomes of placing dental implants in patients taking oral
bisphosphonates: a review of 115 cases. J Oral Maxillofac Surg. 2008;66:223-30.
http://dx.doi.org/10.1016/j.joms.2007.09.019
PMid:18201600
24. Fugazzotto PA, Lightfoot WS,
Jaffin R, Kumar A. Implant placement with or without simultaneous tooth
extraction in patients taking oral bisphosphonates: postoperative healing,
early followup, and the incidence of complications in two private practices. J
Periodontol. 2007;78:1664-9
http://dx.doi.org/10.1902/jop.2007.060514
PMid:17760533
25. Shirota T, Nakamura A, Matsui Y,
Hatori M, Nakamura M, Shintani S. Bisphosphonate-related osteonecrosis of the
jaw around dental implants in the maxilla: report of a case. Clin Oral Implants
Res. 2009;20:1402-8.
http://dx.doi.org/10.1111/j.1600-0501.2009.01801.x
PMid:19793318
26. Bagan JV, Jimenez Y, Murillo J,
Hernandez S, Poveda R, Sanchis JM, et al. Jaw osteonecrosis associated with
bisphosphonates: multiple exposed areas and its relationship to teeth
extractions. Study of 20 cases. Oral Oncol. 2006;42:327-9.
http://dx.doi.org/10.1016/j.oraloncology.2005.08.001
PMid:16275156
27. Ripamonti CI, Cislaghi E, Mariani
L, Maniezzo M. Efficacy and safety of medical ozone (O(3)) delivered in oil
suspension applications for the treatment of osteonecrosis of the jaw in
patients with bone metastases treated with bisphosphonates: Preliminary results
of a phase I-II study. Oral Oncol. 2011;47:185-90.
http://dx.doi.org/10.1016/j.oraloncology.2011.01.002
PMid:21310650
28. Bagan JV, Murillo J, Jimenez Y,
Poveda R, Milian MA, Sanchis JM, et al. Avascular jaw osteonecrosis in
association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med.
2005;34:120-3.
http://dx.doi.org/10.1111/j.1600-0714.2004.00269.x
PMid:15641993
29. Morag Y, Morag-Hezroni M, Jamadar
DA, Ward BB, Jacobson JA, Zwetchkenbaum SR, et al. Bisphosphonate-related osteonecrosis
of the jaw: a pictorial review. Radiographics. 2009;29:1971-84.
http://dx.doi.org/10.1148/rg.297095050
PMid:19926757
30. Ruggiero SL, Fantasia J, Carlson E.
Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for
diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol
Endod. 2006;102:433-41.
http://dx.doi.org/10.1016/j.tripleo.2006.06.004
PMid:16997108
31. Ruggiero SL.
Bisphosphonate-related osteonecrosis of the jaw: an overview. Ann N Y Acad Sci.
2011;1218:38-46.
http://dx.doi.org/10.1111/j.1749-6632.2010.05768.x
PMid:20946580
32. Bagan JV, Jimenez Y, Diaz JM,
Murillo J, Sanchis JM, Poveda R, et al. Osteonecrosis of the jaws in
intravenous bisphosphonate use: Proposal for a modification of the clinical
classification. Oral Oncol. 2009;45:645-6.
http://dx.doi.org/10.1016/j.oraloncology.2008.05.011
PMid:18715813
33. Woo SB, Mawardi H, Treister N.
Comments on “Osteonecrosis of the jaws in intravenous bisphosphonate use:
proposal for a modification of the clinical classification”. Oral Oncol.
2009;45:740.
http://dx.doi.org/10.1016/j.oraloncology.2008.10.001
PMid:19038574
34. Bagán J, Blade J, Cozar JM,
Constela M, García Sanz R, Gómez Veiga F, et al. Recommendations for the
prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in
cancer patients treated with bisphosphonates. Med Oral Patol Oral Cir Bucal.
2007;12:E336-40.
PMid:17664922
35. Marcuzzi A, Zanin V, Crovella S,
Pontillo A. Comments on ‘’Geranylgeraniol- A new potential therapeutic approach
to bisphosphonate associated osteonecrosis of the jaw” by Ziebart T et al.
(2011). Oral Oncol. 2011;47:436-7.
http://dx.doi.org/10.1016/j.oraloncology.2011.02.017
PMid:21411362
36. Bocanegra-Pérez S,
Vicente-Barrero M, Sosa-Hernández M, Knezevic M, Castellano-Navarro JM,
Rodríguez-Millares J. Bisphosphonateassociated osteonecrosis of the jaw. A
proposal for conservative treatment. Med Oral Patol Oral Cir Bucal.
2008;13:E770-3.
PMid:19047964
37. Marx RE, Sawatari Y, Fortin M,
Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis)
of the jaws: risk factors, recognition, prevention, and treatment. J Oral
Maxillofac Surg. 2005;63:1567-75.
http://dx.doi.org/10.1016/j.joms.2005.07.010
PMid:16243172
38. Tirelli G, Biasotto M, Chiandussi
S, Dore F, De Nardi E, Di Lenarda R. Bisphosphonate-associated osteonecrosis of
the jaws: The limits of a conservative approach. Head Neck. 2009; 31:1249.
http://dx.doi.org/10.1002/hed.21019
39. Bagan JV, Jiménez Y, Gómez D,
Sirera R, Poveda R, Scully C. Collagen telopeptide (serum CTX) and its
relationship with the size and number of lesions in osteonecrosis of the jaws
in cancer patients on intravenous bisphosphonates. Oral Oncol. 2008;44:1088-9.
http://dx.doi.org/10.1016/j.oraloncology.2008.01.012
PMid:18396443
40. Kwon YD, Ohe JY, Kim DY, Chung
DJ, Park YD. Retrospective study of two biochemical markers for the risk assessment
of oral bisphosphonate-related osteonecrosis of the jaws: can they be utilized
as risk markers? Clin Oral Implants Res. 2011;22:100-5
http://dx.doi.org/10.1111/j.1600-0501.2010.01965.x
PMid:20946206